BioNeutra Global Corp V.BGA

Every now and then......

[captwade]

The market gives you a gift.  This is one of those times.  This stock is simply under the radar to most people.  An indication of that is revealed on this board.  Since the company went public there has been a total of 14 posts here by 6 people.  According to Stockchase, this company has never been mentioned on BNN, not once.  There is no analyst coverage.  The company appears to do no promotion whatsoever.  

This company has a twin, Ceapro {CZO}   The similarities are amazing, including the fact that they are located in the same city, about 30 blocks apart.  Both are currently commissioning new plants,  both have patents on their lead products,  both recently doubled staff, both work closely with the U of A,  etc.  I have positions in both and I feel they have about equal potential going forward.  

The reason I mention Ceapro here is that certain metrics make BGA look pretty attractive when compared to Ceapro.  If we look at price to cash flow and price to sales we see that this company is available at one quarter of the same metrics on Ceapro.  It would appear to be quite a bargain compared to Ceapro  especially when one considers that  those metrics have been as much as five times higher in the past .  So, even with Ceapro's  metrics severly depressed BGA is still four times cheaper. 

In summary, if we apply those two metrics to equally to CZO and BGA, then BGA would be worth  $2.00  right now.

My opinion only.

[billy4325]

You may want to look at the FDA and IMOs (see richbearhunter's post in June).  Also look into IMO's effects on blood sugar.   CZO and BGA are very different companies, but they may have one thing in common.  CZO was very profitable a couple years ago (very high gross margins and also had good net income), however their sales have declined and now the company is losing

[captwade]

Yes, good points Billy.   And you are right, above all else I will be watching the sales figures. I first bought Ceapro because it had actual earnings and we were told to expect gross margins to increase from an already great figure of 73%.  Then we saw how rapidly things can change. BGA does in fact remind me of Ceapro before Echelon got ahold of it.  I admit to probably not

[runwiththebulls]

I would be careful. I was optimistic about this company but the FDA's crack down on fibre now scares me. And why can't I buy Vitafiber? I've tried a few times and they won't ship to a Canadian address. 

[captwade]

I'm as careful as one can be with these little companies.  I will be watching only one thing, and that is the gross sales. Sort of hopeful for the next quarter, due at the end of the month, because it is the first quarter following their European launch with Lehvoss.  As long as the upward trend in sales continues I will stay with these guys.   I would consider the fact that